2026 ICD-10-CM Diagnosis Code T45.625SAdverse effect of hemostatic drug, sequela

ICD-10-CM Codes›S00–T88›T36-T50›T45

ICD-10-CM T45.625S
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T45.625S is a billable ICD-10-CM diagnosis code for adverse effect of hemostatic drug, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. Coders also document this condition as aprotinin adverse reaction. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.

Code Identity

ICD-10-CM Code
T45.625S
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of hemostatic drug, sequela
Short Description
Adverse effect of hemostatic drug, sequela
Same as the full description in the CMS dataset.
Parent Code
T45.625
Adverse effect of hemostatic drug

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT45Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified
This CodeT45.625SAdverse effect of hemostatic drug, sequela

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T45.625S.

Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

T45.625S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Aprotinin adverse reaction
  • Hemostatic adverse reaction
  • Tranexamic acid adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ075
Poisoning/toxic effect/adverse effects/underdosing, sequela
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Aminocaproates

    amino derivatives of caproic acid. included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the amino caproic acid structure.

  • Aminocaproic Acid

    an antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

  • Aprotinin

    a single-chain polypeptide derived from bovine tissues consisting of 58 amino-acid residues. it is an inhibitor of proteolytic enzymes including chymotrypsin; kallikrein; plasmin; and trypsin. it is used in the treatment of hemorrhage associated with raised plasma concentrations of plasmin. it is also used to reduce blood loss and transfusion requirements in patients at high risk of major blood loss during and following open heart surgery with extracorporeal circulation. (reynolds jef(ed): martindale: the extra pharmacopoeia (electronic version). micromedex, inc, englewood, co, 1995)

  • Tranexamic Acid

    antifibrinolytic hemostatic used in severe hemorrhage.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect		Under­dosing
Aminocaproic acidT45.621T45.622T45.623T45.624T45.625T45.626
Antifibrinolytic drugT45.621T45.622T45.623T45.624T45.625T45.626
AprotininT45.621T45.622T45.623T45.624T45.625T45.626
Epsilon amino-caproic acidT45.621T45.622T45.623T45.624T45.625T45.626
HemostaticT45.621T45.622T45.623T45.624T45.625T45.626
Hemostatic::drug, systemicT45.621T45.622T45.623T45.624T45.625T45.626
Tranexamic acidT45.621T45.622T45.623T45.624T45.625T45.626

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T45.625S to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.5 Lte efct advrs efct drug
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E934.8 Adv eff blood agent NEC
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T45.625SOverview

Is T45.625S (Adverse effect of hemostatic drug) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of hemostatic drug, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T45.625S mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of hemostatic drug itself has resolved, not the original event.

What MS-DRG does T45.625S group to?

On inpatient claims, adverse effect of hemostatic drug, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T45.625S be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of hemostatic drug, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is T45.625S exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of hemostatic drug, sequela on inpatient claims.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.